← CRISPR-Cas9 Art. 54 Case Study
EPO Art. 54(2) · Novelty Escape Guide
5 Ways to Escape a Novelty Rejection
From the CRISPR-Cas9 Art. 54 case study: five proven amendment strategies that survived EPO examination — with claim language, escape logic, and ClaimForge pipeline mapping.
Quelle: CRISPR-Cas9 Art. 54 Case Study
5
Bewährte EPO Art. 54(2) Escape-Strategien aus CRISPR-Biotech-Prosecution
Genus Restriction
| Rejection |
Jinek 2012 anticipates the sgRNA + Cas9 RNP genus |
| Escape Logic |
Substitute SpCas9 with a distinct ortholog (SaCas9, Cas12a/Cpf1) with different PAM requirements and guide-RNA architecture not disclosed in D1 |
| Claim Language |
…wherein the Cas9 endonuclease is a SaCas9 ortholog recognising a NNGRRT PAM sequence… |
| ClaimForge Action |
OA-Agent identifies Cas9 genus anticipation → Gap analysis surfaces PAM/guide-architecture distinctions → amendment + re-search on ortholog claims |
Confidence: 82%
Structural Specificity
| Rejection |
D1 discloses RNP complex formation in prokaryotic in vitro assays |
| Escape Logic |
Restrict to intracellular delivery of pre-formed RNP via electroporation or lipid nanoparticle (LNP) into human cells — a structural claim element absent from any prokaryotic in vitro reference |
| Claim Language |
…wherein the RNP complex is introduced into a human cell by electroporation or lipid nanoparticle delivery… |
| ClaimForge Action |
OA-parsing extracts delivery-mode gaps → claims amended with delivery element from spec [0042], [0055] → re-search confirms no prior art on RNP + LNP human delivery combination |
Confidence: 78%
Mechanism Specificity
| Rejection |
sgRNA + Cas9 cleavage mechanism is fully anticipated; repair pathway not claimed |
| Escape Logic |
Narrow claim scope to HDR (homology-directed repair) using a specific ssODN donor with defined homology arm lengths (≥40 nt); NHEJ-only prior art cannot anticipate HDR-specific limitation |
| Claim Language |
…further comprising introducing a single-stranded oligonucleotide donor (ssODN) having homology arms of at least 40 nucleotides flanking the target DNA cleavage site… |
| ClaimForge Action |
Agent distinguishes NHEJ vs HDR scope → amendment adds ssODN donor + arm-length limitation → re-search specifically screens for HDR + ssODN prior art |
Confidence: 74%
Use-Based Novelty
| Rejection |
General CRISPR editing in human cells anticipated by Cong 2013 / Mali 2013 |
| Escape Logic |
Restrict to treatment of a specific genetic disease (e.g. ex vivo correction of HSCs in sickle-cell disease) — a therapeutic-use claim scope not disclosed in general in vitro editing references |
| Claim Language |
…for use in treating sickle-cell disease, wherein the target DNA sequence comprises the HbS mutation at codon 6 of the beta-globin gene… |
| ClaimForge Action |
OA-parsing surfaces Cong/Mali anticipation → amendment templates use-claim with specific indication and target locus → re-search filters on disease-specific therapeutic art |
Confidence: 71%
Claim Category Shift
| Rejection |
Product and use claims anticipated; in vitro cell editing fully disclosed |
| Escape Logic |
Reframe as a method of treating a patient comprising administering a therapeutically effective composition — in vivo administration and clinical dosing step are absent from all cited in vitro prior art |
| Claim Language |
A method of treating a genetic disorder in a patient comprising: administering to the patient a therapeutically effective amount of an RNP complex… |
| ClaimForge Action |
Agent identifies claim category vulnerability → converts product/use claim to method-of-treatment with patient + dosing step → full counter-argument draft on Art. 54(2) single-document rule |
Confidence: 68%
Step 1
OA Parsing
Identifies the Art. 54(2) rejection type and primary reference
Step 2
Gap Analysis
Scores each prior-art document against amended claim features
Step 3
Amendment Draft
Generates claim language with spec-anchor references
Step 4
Counter-Arguments
Writes EPO-format response addressing single-document anticipation rule
Step 5
Re-Search
Runs Espacenet + Google Patents on amended claims to validate escape
Run Your Own Novelty Escape Loop
Upload your Art. 54 OA and let ClaimForge identify which escape strategy fits your claim — 90 min vs. 20+ hours manually.